In this context, the 55% cut-off of Ki67 LI could be an important prognostic factor, which is not included in the current NEC WHO classification and consequently, guidelines recommend the same treatment for both low and high Ki67 LI NECs. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.